Literature DB >> 35586431

KRAS Inhibitors and Target Engagement Technology: From Undruggable to Druggable Targets in Cancer Therapeutics.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2022        PMID: 35586431      PMCID: PMC9109516          DOI: 10.1021/acsmedchemlett.2c00130

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  6 in total

Review 1.  Drugging "undruggable" genes for cancer treatment: Are we making progress?

Authors:  Michael J Duffy; John Crown
Journal:  Int J Cancer       Date:  2020-08-07       Impact factor: 7.396

Review 2.  RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients.

Authors:  Umberto Malapelle; Francesco Passiglia; Chiara Cremolini; Maria Lucia Reale; Francesco Pepe; Pasquale Pisapia; Antonio Avallone; Diego Cortinovis; Alfonso De Stefano; Matteo Fassan; Gabriella Fontanini; Domenico Galetta; Calogero Lauricella; Angela Listì; Fotios Loupakis; Fabio Pagni; Filippo Pietrantonio; Sara Pilotto; Luisella Righi; Andrea Sartore Bianchi; Hector Soto Parra; Marcello Tiseo; Michela Verzè; Giancarlo Troncone; Silvia Novello
Journal:  Eur J Cancer       Date:  2021-02-12       Impact factor: 9.162

Review 3.  Drugging the Next Undruggable KRAS Allele-Gly12Asp.

Authors:  Qinheng Zheng; D Matthew Peacock; Kevan M Shokat
Journal:  J Med Chem       Date:  2022-02-15       Impact factor: 7.446

Review 4.  Resistance looms for KRAS G12C inhibitors and rational tackling strategies.

Authors:  Junmin Zhang; Juanhong Zhang; Qing Liu; Xing-Xing Fan; Elaine Lai-Han Leung; Xiao-Jun Yao; Liang Liu
Journal:  Pharmacol Ther       Date:  2021-12-03       Impact factor: 12.310

Review 5.  Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies.

Authors:  Anne-Laure Désage; Camille Léonce; Aurélie Swalduz; Sandra Ortiz-Cuaran
Journal:  Front Oncol       Date:  2022-02-16       Impact factor: 6.244

Review 6.  Targeting KRAS mutant lung cancer: light at the end of the tunnel.

Authors:  Matthias Drosten; Mariano Barbacid
Journal:  Mol Oncol       Date:  2022-01-18       Impact factor: 6.603

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.